In an eleventh hour effort before a projected government shutdown, the US Food and Drug Administration (FDA) laid out its plan for forging ahead with the regulation of laboratory-developed tests (LDTs). The FDA’s approach is notably straightforward:
- Labratories that develop LDTs for clinical use are considered manufacturers of in vitro diagnostic medical devices (IVDs) for commercial distribution.
- These labs, according to the FDA’s proposal, must ultimately comply with the FDA’s pre-existing IVD regulations.
This contrasts with previous proposals from the FDA and Capitol Hill, which often comprised more complex or conditional regulatory frameworks. The approach indicated by the FDA’s proposed rule, however, suggests an intention to integrate LDTs fully into the regulatory apparatus currently applied to IVDs.
The LDT rule proposed by the FDA comes amidst an impending government shutdown, highlighting the urgency of the need for clear regulatory standards for LDTs. These tests, conceived and executed in a single lab, present unique challenges to regulatory mechanisms, often straddling the line between research and direct clinical application. The new proposal aims to clarify their regulatory status, potentially leading to significant changes in the LDT landscape.
The implications for legal professionals operating in the health sector – particularly those working in or with labs that design and use LDTs – are significant. The proposed rule may necessitate a full review of existing operations to ensure compliance with FDA’s established IVD requirements. A careful monitoring of the FDA’s next steps in implementing this proposal will be crucial moving forward.